title: Spontaneous delayed recovery of perfusion after thrombolyzed acute myocardial infarction: is it predictable before discharge?
abstract: In patients with thrombolyzed acute myocardial infarction, early assessment of the final infarct size is difficult because spontaneous recovery of perfusion and function of the left ventricle may be delayed. This study was undertaken to evaluate the ability of predischarge low-dose dobutamine echocardiography to predict late spontaneous recovery of perfusion assessed by single-photon emission computed tomography after acute myocardial infarction. We prospectively studied 53 consecutive patients with myocardial infarction treated with thrombolysis. Low-dose dobutamine echocardiography and resting (99m)Tc-sestamibi single-photon emission computed tomography (MIBI SPECT) were performed 4 +/- 2 days after infarction. A follow-up SPECT study was carried out in 45 patients after 6 months. Myocardial recovery was defined as a reduction of SPECT defect size by more than 10% at follow-up compared with the early study. In 25 of the 45 patients, the size of the left ventricular perfusion defect decreased significantly from 42% +/- 16% to 27% +/- 10% (group 1), whereas in the remaining 20 patients it showed no significant change (group 2). Predischarge low-dose dobutamine echocardiography showed a significant improvement in wall motion score index compared with baseline in group 1, from 1.62 +/- 0.28 to 1.41 +/- 0.24, P <.001, whereas in group 2 this index remained without significant change. Predischarge low-dose dobutamine echocardiography is an accurate tool for prediction of late recovery of myocardial perfusion after acute myocardial infarction treated with thrombolysis.
authors.affiliation: Karolinska Institutet, Department of Cardiology, Stockholm Söder Hospital, Stockholm, Sweden. Samad@medklin.sos.sll.se
authors.forename: B A
authors.initials: BA
authors.lastname: Samad
authors.forename: J
authors.initials: J
authors.lastname: Höjer
authors.forename: F
authors.initials: F
authors.lastname: Bouvier
authors.forename: K
authors.initials: K
authors.lastname: Jensen-Urstad
authors.forename: M
authors.initials: M
authors.lastname: Frick
authors.forename: H
authors.initials: H
authors.lastname: Ruiz
authors.forename: J
authors.initials: J
authors.lastname: Hulting
authors.forename: M
authors.initials: M
authors.lastname: Jensen-Urstad
mesh_terms: D000318:Adrenergic beta-Agonists / Q000008:administration & dosage; D000368:Aged; D003326:Coronary Circulation; D004280:Dobutamine / Q000008:administration & dosage; D025401:Echocardiography, Stress; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000000981:diagnostic imaging* / Q000188:drug therapy; D009206:Myocardium / Q000473:pathology; D011379:Prognosis; D011446:Prospective Studies; D020127:Recovery of Function / Q000502:physiology; D017256:Technetium Tc 99m Sestamibi; D015912:Thrombolytic Therapy; D015899:Tomography, Emission-Computed, Single-Photon
chemical_list: D000318:Adrenergic beta-Agonists; D004280:Dobutamine; D017256:Technetium Tc 99m Sestamibi